Resource Logo

Study of CD28-mediated costimulation in long term non progressor, asymptomatic and symptomatic HIV+ patients.


Int Conf AIDS. 1996 Jul 7-12;11(2):70 (abstract no. We.A.3074). Unique

Objective: To study the effect of CD28 mediated costimulation on lymphoproliferation to anti-CD3 monoclonal antibody (mAb) in patients at different stages of HIV infection. Methods: Blood was collected from 6 long term non progressor (LTnP) subjects ( Documented seropositivity from at least 7 years, asymptomatics with CD4+ cellsgreater than 500/mm3), 26 HIV+ asymptomatic patients (CDC stage A1-A2) and 6 symptomatic patients (CDC stage C3); 6 HIV - healthy subjects were tested as controls. Separated peripheral blood mononuclear cells (1x106 cells/ml) were cultured in 96-well flat bottom cell culture plates in the presence of anti-CD3 mAb alone or anti-CD3 and anti-CD28. After three days of culture proliferation was assessed by tritiated thymidine incorporation. Results: There was a significant decrease in lymphoproliferation to anti-CD3 mAb alone or to anti-CD3 and anti-CD28 mAbs in AIDS patients compared to the other groups. In asymptomatics and LTnP the addition of anti-CD28 mAb caused a significant increase in lymphoproliferation to anti-CD3 (p is less than 0.05); this effect was more evident in LTnP. Conclusions: In HIV+ asymptomatic and LTnP patients the addition of anti-CD28 mAb causes an increase in response to anti-CD3 more evident than in HIV- subjects. This indicates that the costimuatory pathway is unaffected and even increased in the asymptomatic phase of infection whereas it is unable to restore proliferative response to anti-CD3 in AIDS patients.

*Acquired Immunodeficiency Syndrome/IMMUNOLOGY *Antibodies, Monoclonal/PHARMACOLOGY *Antigens, CD3/IMMUNOLOGY *HIV Infections/IMMUNOLOGY *Lymphocytes/CYTOLOGY


Information in this article was accurate in January 30, 1997. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.